What do systematic reviews say?

Summary of findings: insulin degludec vs insulin detemir

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 802 participants
  Low

Summary of findings: insulin degludec vs insulin detemir

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 454 participants
  Low

Summary of findings: insulin degludec vs insulin detemir

Summary of findings: insulin degludec showed no clear difference in severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with insulin detemir (low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 1.17 [0.81, 1.69]
  2 studies · 802 participants
  Low

Summary of findings: insulin degludec vs insulin detemir

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 453 participants
  Low

Summary of findings: insulin degludec vs insulin detemir

Summary of findings: insulin degludec showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with insulin detemir (low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 1.12 [0.51, 2.46]
  2 studies · 802 participants
  Low

Summary of findings: insulin degludec vs insulin detemir

Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin detemir (low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 1.25 [0.76, 2.05]
  2 studies · 802 participants
  Low

Summary of findings: insulin degludec vs insulin detemir

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 802 participants
  Low

Summary of findings: insulin degludec vs insulin glargine

It is very uncertain whether summary of findings: insulin degludec changes all‐cause mortality compared with insulin glargine (very low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  Peto OR 1.34 [0.15, 11.93]
  3 studies · 973 participants
  Very low

Summary of findings: insulin degludec vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1042 participants
  Very low

Summary of findings: insulin degludec vs insulin glargine

Summary of findings: insulin degludec showed no clear difference in severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with insulin glargine (low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 1.22 [0.82, 1.82]
  3 studies · 970 participants
  Low

Summary of findings: insulin degludec vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 970 participants
  Low

Summary of findings: insulin degludec vs insulin glargine

Summary of findings: insulin degludec showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with insulin glargine (low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 1.39 [0.59, 3.27]
  3 studies · 970 participants
  Low

Summary of findings: insulin degludec vs insulin glargine

Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.92 [0.58, 1.46]
  3 studies · 970 participants
  Low

Summary of findings: insulin degludec vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1388 participants
  Low